NCT07524855 (HLD-0117) is a Phase 1 clinical trial of HLD-0117 in Metastatic Breast Cancer, sponsored by Halda Therapeutics OpCo, Inc..

Who is sponsoring NCT07524855?

NCT07524855 is sponsored by Halda Therapeutics OpCo, Inc..

What drugs are being tested in NCT07524855?

Interventions in NCT07524855: HLD-0117.

What condition does NCT07524855 study?

NCT07524855 studies Metastatic Breast Cancer.

Is NCT07524855 still recruiting?

NCT07524855 is currently recruiting now. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT07524855: HLD-0117

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

Recruiting now Phase 1 Last updated 13 April 2026

What this trial tests

Phase 1 trial testing HLD-0117 in Metastatic Breast Cancer in 33 participants. Currently enrolling.

Timeline

31 March 2026

Primary endpoint
30 April 2028

30 April 2028

Quick facts

Lead sponsor	Halda Therapeutics OpCo, Inc.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	31 March 2026
Primary completion	30 April 2028
Estimated completion	30 April 2028
Sites	3 locations across United States

Drugs / interventions tested

HLD-0117

Conditions studied

Metastatic Breast Cancer — all drugs for Metastatic Breast Cancer →

Sponsor

Halda Therapeutics OpCo, Inc. — full company profile →

Who can join

18 and older, female only, with Metastatic Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metastatic Breast Cancer

Currently open trials in the same condition.

NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT07347600 — A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, · recruiting
NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07524855 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Halda Therapeutics OpCo, Inc.
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07524855.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing